HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding.

AbstractOBJECTIVES:
To quantify the change in work productivity and activities of daily living in North American women with heavy menstrual bleeding (HMB) treated with estradiol valerate/dienogest (E2V/DNG; Qlaira(®)/Natazia(®)) compared to placebo.
METHODS:
Women in the United States and Canada, aged 20-53 years with an objective diagnosis of HMB and no recognizable anatomical pathology, were treated with E2V/DNG or placebo for seven cycles (196 days). Main outcome measures included work productivity (i.e., productivity while at work) and activities of daily living measured using a modified Work Productivity and Activity Impairment Questionnaire (mWPAI) on a Likert scale from 0 to 10 (higher values denote higher impairment levels).
RESULTS:
In both countries, significant improvement was observed between baseline and end of treatment in work productivity and activities of daily living impairment. The improvements in work productivity and activities of daily living with E2V/DNG treatment relative to placebo ranged from 37.2% to 39.2% across both countries. Monthly gains due to E2V/DNG treatment (net of placebo improvement) associated with improvement in work productivity were estimated to be US$80.2 and Can$70.8 (US$58.5) and those associated with improvement in activities of daily living were estimated to be US$84.9 and Can$73.5 (US$60.7).
CONCLUSIONS:
E2V/DNG was shown to have a consistent positive impact on work productivity and activities of daily living in U.S. and Canadian women with HMB. In addition, these improvements in work productivity and activities of daily living were associated with a reduction in HMB-related monetary burden compared to the placebo group.
AuthorsRadoslaw Wasiak, Anna Filonenko, David J Vanness, Amy Law, Mark Jeddi, Kim U Wittrup-Jensen, Donald E Stull, Steven Siak, Jeffrey T Jensen
JournalJournal of women's health (2002) (J Womens Health (Larchmt)) Vol. 22 Issue 4 Pg. 378-84 (Apr 2013) ISSN: 1931-843X [Electronic] United States
PMID23586801 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Contraceptives, Oral, Hormonal
  • Drug Combinations
  • estradiol valerate-dienogest
  • Estradiol
  • Nandrolone
Topics
  • Activities of Daily Living
  • Adult
  • Contraceptives, Oral, Hormonal (therapeutic use)
  • Double-Blind Method
  • Drug Combinations
  • Efficiency
  • Estradiol (analogs & derivatives, therapeutic use)
  • Female
  • Humans
  • Menorrhagia (drug therapy)
  • Middle Aged
  • Nandrolone (analogs & derivatives, therapeutic use)
  • Treatment Outcome
  • Work
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: